Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Asset Writedowns and Impairment: 2014-2018

Historic Asset Writedowns and Impairment for Ironwood Pharmaceuticals (IRWD) over the last 1 years, with Dec 2018 value amounting to $6,000.

  • Ironwood Pharmaceuticals' Asset Writedowns and Impairment was N/A to $6,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $154.0 million, marking a year-over-year change of. This contributed to the annual value of $151.8 million for FY2018, which is N/A change from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Asset Writedowns and Impairment of $6,000 as of Q4 2018, which was down 100.00% from $151.8 million recorded in Q3 2018.
  • In the past 5 years, Ironwood Pharmaceuticals' Asset Writedowns and Impairment ranged from a high of $151.8 million in Q3 2018 and a low of -$6,000 during Q2 2014.
  • Moreover, its 2-year median value for Asset Writedowns and Impairment was $1.1 million (2016), whereas its average is $38.5 million.